Poultry Diseases Department, Faculty of Veterinary Medicine, Assuit University, Assuit, Egypt.
Avian and Rabbit Diseases Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Vet Res Commun. 2020 Nov;44(3-4):147-157. doi: 10.1007/s11259-020-09782-z. Epub 2020 Sep 27.
The selection of the right IBD control strategy is primarily based on the choice of the appropriate vaccine strain. High maternal IBD-specific antibodies (Abs) compete with the efficacy IBD vaccine, which necessitates the application of intermediate-plus vaccine strain.
A comparative experimental study was designed for evaluation of four different commercially available intermediate-plus IBD vaccines in commercial broilers before complete weaning of IBD-specific maternal Abs.
As determined by IBD- specific quantitative real-time polymerase chain reaction, three tested vaccine strains (228E, Winterfield H2512, and Winterfield 2512) were able to establish in the bursal tissues as early as six hours (hrs) post-vaccination (PV). Both the 228E and the Winterfield H2512 strains vaccinated groups had the highest viral load and replication rate in the bursal tissues at 24, 36, 48 and 72 hrs PV. Earlier seroconversion, 7-14 days PV, was observed in the case of Winterfield H2512, 228E, and Winterfield 2512 vaccinated birds compared to the Lukert vaccinated birds. The 228E strain was more virulent and induces the highest lesion score with severe degrees of lymphocyte depletion and necrosis which persisted up to 28 days PV.
Overall, the different intermediate-plus IBD strains possess variable early kinetics in the bursal tissues and eliciting antibody (Ab) responses differently withdifferent degrees of bursal lesions. The assessment of the intrabursal vaccine load together with humoral immunity and bursal damage lesion score are fundamental parameters in the evaluation of the intermediate-plus IBD vaccines.
IBD 控制策略的选择主要基于疫苗株的选择。高母体 IBD 特异性抗体(Abs)会与 IBD 疫苗的疗效竞争,这就需要使用中-强疫苗株。
在 IBD 特异性母源 Abs 完全断奶前,设计了一项比较性实验研究,评估四种不同的商业中-强 IBD 疫苗在商品肉鸡中的应用。
通过 IBD 特异性定量实时聚合酶链反应(PCR)确定,三种测试的疫苗株(228E、Winterfield H2512 和 Winterfield 2512)能够在接种后 6 小时(hrs)内建立在法氏囊组织中。在接种后 24、36、48 和 72 小时,228E 和 Winterfield H2512 疫苗接种组的法氏囊组织中病毒载量和复制率最高。与 Lukert 疫苗接种组相比,Winterfield H2512、228E 和 Winterfield 2512 疫苗接种组的血清转换更早,在接种后 7-14 天即可检测到抗体。228E 株更具毒力,可诱导最高的病变评分,伴有严重程度的淋巴细胞耗竭和坏死,持续至接种后 28 天。
总之,不同的中-强 IBD 株在法氏囊组织中具有不同的早期动力学特征,并以不同程度的法氏囊病变引起不同的抗体(Ab)反应。法氏囊内疫苗负荷量以及体液免疫和法氏囊损伤病变评分的评估是中-强 IBD 疫苗评估的基本参数。